Skip to main content
. 2022 Jan 17;9(9):2105587. doi: 10.1002/advs.202105587

Figure 6.

Figure 6

Hepatic loss of SDHAF4 activates arginine‐NO cycle to improve insulin sensitivity in mice. a) Metabolomics analysis for Z‐score plot of global metabolic profiles among all the serum samples of control and Sdhaf4 Alb KO mice, n = 6. b) NO level in serums of control and Sdhaf4 Alb KO mice, n = 8. c) NO level in serums of regular feeding and ADF intervened mice, n = 8. d) mRNA levels of Slc7a1, Asl, Ass1, Nos1, Nos2, and Nos3 in livers of control and Sdhaf4 Alb KO mice or regular feeding and ADF intervened mice, n = 6. e,f) Immunoblots of NOS1, NOS2, and NOS3 in livers of control and Sdhaf4 Alb KO mice or regular feeding and ADF intervened mice, n = 6. g) Glucose tolerance test in control and Sdhaf4 Alb KO mice with or without L‐NAME treatment for 2 weeks, n = 6. h) Glucose tolerance test in regular feeding and ADF intervened mice with or without L‐NAME treatment for 4 weeks, n = 6. i) Graphic illustration of cells co‐culture experiments. j) Immunoblots of p‐Akt in C2C12 cells and k) 3T3‐L1 cells that co‐cultured with primary hepatocytes from control and Sdhaf4 Alb KO mice followed with or without insulin challenge for 15 min, l) statistical analysis of p‐Akt level, n = 3. m) cGMP level in the liver, muscle, and iWAT from control and Sdhaf4 Alb KO mice at the age of 8 weeks, n = 8. n) cGMP level in the liver, muscle, and iWAT from regular feeding and ADF intervened mice for 8 weeks, n = 8. o) cGMP level in the liver, p) muscle, and q) iWAT from control and Sdhaf4 Alb KO mice with or without L‐NAME treatment for 2 weeks, n = 3. Values are mean ± SEM, *p < 0.05, **p < 0.01.